AstraZeneca PLC
AZN
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $252.3B
$162.70
▼ -1.26%
P/E
16.45
Mkt Cap
$252.3B
52-Wk Range
$145.80–$212.71
52-Week Range
$145.80 - $212.71
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 0.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Diversified blockbuster portfolio with multiple revenue-generating assets across therapeutic areas
- Global distribution network and established relationships with primary and specialty care physicians worldwide
- Strong R&D pipeline enhanced by strategic AI-driven partnerships and collaborations with leading biotech innovators
- Proven expertise in complex drug development, manufacturing, and commercialization across regulated markets
- Established market presence in high-value oncology and rare disease segments with significant pricing power
Bear Case
2 risks
- Low volatility (beta 0.2).
- Premium valuation to Large Cap Pharma peers
Growth
Stable outlook
Expanding oncology pipeline with innovative targeted therapies addressing high-unmet medical needs
Value
Premium valuation to Large Cap Pharma peers
Momentum
Weak
-10.4% over 3m
Quality
Excellent
Excellent business quality
Dividend
Modest
1.98% yield
Smart-money signal
Who's buying AZN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 30, 2026
JUL 27, 2026
Reported EPS of $2.63 vs $2.50 consensus (+5.2% surprise). Revenue of $15.4B vs $15.4B expected (-0.3%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+5.2%
Revenue trend · last 8Q
—
+24%
+7%
+12%
+12%
+4%
+13%
+5%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$13.6B
$14.9B
$13.6B
$14.5B
$15.2B
$15.5B
$15.3B
$15.2B
Margins · last 8Q
Gross
73.5%
Operating
20.2%
Profit
16.3%
Wall Street consensus
4 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: CICC · Aug 23, 2026
vs Industry
How AZN stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related